Stock Market & Financial Investment News

News Breaks February 26, 2013 09:02 EDT ARWR ArrowHead Research to publish data of ARC-520 study Arrowhead Research announced the publication of data demonstrating multi-log reductions in hepatitis B viral DNA and proteins lasting over 30 days after a single injection in animal models. This suggests that Arrowhead's RNAi-based candidate ARC-520 has the potential to treat chronic hepatitis B virus infection in a fundamentally different manner, with the goal of achieving a functional cure. The paper, entitled "Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection," by Wooddell et al, was published online ahead of print in the journal Molecular Therapy. In the publication, Arrowhead scientists describe the use of a novel Dynamic PolyConjugate technology to deliver small interfering RNAs designed against the hepatitis B virus. News For ARWR From The Last 14 Days Check below for free stories on ARWR the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. There are no results for ARWR Sign up for a free trial to see the rest of the stories you've been missing.